A5042945019- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Platelet Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Glutathione Transferases and Polymorphisms
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Glioma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Brain Metastases and Treatment
- Blood disorders and treatments
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chronic Myeloid Leukemia Treatments
Eli Lilly (United States)
2013-2025
Loxo Oncology at Lilly (United States)
2023
Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with
Selpercatinib is a highly selective and potent CNS-active RET kinase inhibitor approved for the treatment of fusion-positive NSCLC based on results phase I/II trial LIBRETTO-001 (NCT03157128). The final data reported. Patients with advanced, (identified by NGS, PCR or FISH) who were naïve had previously received platinum-based chemotherapy enrolled at selpercatinib dose 160 mg BID. primary end point was objective response rate (ORR) RECIST 1.1 assessed an independent review committee....
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128 ) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months additional follow-up, we report the final efficacy and safety results patients with RET fusion–positive non–small cell lung cancer (NSCLC) who had previously received platinum-based chemotherapy (N = 247) or were treatment-naïve 69). The objective response rate (ORR) was 62% for pretreated 83% patients. Duration...
746 Background: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor with CNS activity, is approved in multiple countries for the treatment of RET-activated cancers. This update includes more patients (pts, n=52) 16 months (mo) longer follow-up (data cut-off: 13Jan2023) fusion+ solid tumors other than lung/thyroid focus on GI histologies. Methods: The phase 1/2 LIBRETTO-001 trial (NCT03157128) enrolled pts locally advanced/metastatic tumors. 51/52 received...
"HSR24-128: Real-World Treatment Patterns and Effectiveness of Selpercatinib in Patients With Locally Advanced/Metastatic Non–Small Cell Lung Cancer the US" published on 05 Apr 2024 by National Comprehensive Network.
10009 Background: Activating RET alterations are oncogenic drivers of select pediatric and adult cancers. Selpercatinib is a first-in-class, highly selective potent, CNS active kinase inhibitor. The manageable toxicity profile durable anti-tumor activity in RET-altered cancers demonstrated the LIBRETTO-001 phase 1/2 trial led to global approvals selpercatinib adults adolescents with thyroid cancer NSCLC. Methods: LIBRETTO-121 (JZJJ) multicenter pts 0.5-21 years (yrs) age advanced, solid or...
Selpercatinib is indicated for locally advanced/metastatic RET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness comparing selpercatinib with other first-line treatments in non-small cell lung cancer (NSCLC), medullary thyroid (MTC), (TC). This study analyzed patient LIBRETTO-001 compared outcomes (time to treatment discontinuation {TTD}, time next death...
Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab in clinical trials postmarketing reports.Data from patients exposed to across nine were reviewed for IRRs. Blood samples also analyzed pre-existing E anti-galactose-α-1,3-galactose (anti-α-Gal) antibodies.In trials, IRRs identified 70 485 (14.4%). The most frequent symptoms included flushing,...
•Long-term patient-reported outcomes (PROs) in patients with RET-driven cancers from the LIBRETTO-001 trial were reported.•Most had improved or stable quality of life during long-term treatment selpercatinib.•Physical function and symptoms such as dyspnea, appetite loss, insomnia, fatigue, pain also remained stable.•These findings further support selpercatinib standard care for advanced cancers. BackgroundThis post-hoc retrospective study describes REarranged Transfection (RET)-altered...
3150 Background: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor with CNS activity, is approved in multiple countries for the treatment of RET-activated cancers. Current indications mutant disease are limited to MTC. This analysis examined if selpercatinib was effective non-MTC, mutation positive tumors whether certain mutations demonstrated better activity (n=23; data cut-off: 13Jan2023). Methods: The phase 1/2 LIBRETTO-001 trial (NCT03157128) enrolled pts...
Selpercatinib is a selective RET inhibitor approved for treatment of RET-activated cancers. Adverse events (AEs) are manageable with dose modifications. This post hoc analysis characterized selpercatinib's clinical safety profile after long-term follow-up in the population LIBRETTO-001.
This study described real-world patient characteristics and outcomes among selpercatinib-treated patients in the United States, using Flatiron Health electronic health record-derived deidentified database (FHD) for advanced/metastatic non-small cell lung cancer (a/mNSCLC) Optum's de-identified Clinformatics
This study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) examine treatment healthcare resource utilization patterns this patient population in a United States (US) community-based oncology practice setting over time.
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
"HSR22-130: A Retrospective Cohort Study of Selpercatinib-Treated Patients With Advanced/Metastatic Non-Small Cell Lung Cancer: Preliminary Findings From a Real-World Database in the United States" published on 31 Mar 2022 by National Comprehensive Cancer Network.